Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2022

Stockholders Equity Note [Abstract]

Schedule of Stock-Based Compensation Expense

The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations (in thousands):

	Three Months Ended March 31,
	2022		2021
Cost of revenue	$	25	$	13
Research, development and clinical trials expenses		321		197
Selling, general and administrative expenses		1,964		902
	$	2,310	$	1,112